Stocks · News reference
License allows the Company to commence large-scale extraction of castanospermine from the seeds of Castanospermum australeCompany will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
60 Degrees (NASDAQ:SXTP) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.86) by 4.65 percent. This is a 82.04 percent increase over losses of $(5.01) per share from the
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday's after-market session. The company's market cap stands at $4.5 million. As per the news, the Q2 earnings report
60 Degrees Pharmaceuticals announced a private placement of 574,713 shares at $1.74 per share, expected to raise approximately $1.0 million in gross proceeds before fees. The offering includes series A and B warrants with exercise prices of $1.49 per share. The company plans to use net proceeds for working capital and general corporate purposes.